Die Identifikation transkriptioneller Biomarker für periphere Polyneuropathien
The identification of transcriptional biomarkers for peripheral polyneuropathies
by Ann-Kathrin Kuse
Date of Examination:2024-11-13
Date of issue:2024-09-24
Advisor:Prof. Dr. Michael Werner Sereda
Referee:Prof. Dr. Michael Werner Sereda
Referee:Prof. Dr. Brit Mollenhauer
Files in this item
Name:Diss_SUB ohne Lebenslauf.pdf
Size:4.10Mb
Format:PDF
This file will be freely accessible after 2024-12-11.
Abstract
English
Peripheral polyneuropathies are a heterogeneous group of widespread diseases of the peripheral nerves that can be caused by numerous factors. Differentiating between different types of polyneuropathies and identifying their causes is of the utmost importance for patients and practitioners when it comes to therapy and prognosis assessment. Currently, diagnosis is based on various non-invasive and invasive clinical, laboratory, electrophysiological and histological examinations as well as the response to certain therapies. However, the differential diagnosis of polyneuropathies is often difficult due to non-specific findings and atypical clinical manifestations. Despite the extensive diagnostic possibilities, the aetiology often remains unclear. The identification of reliable biomarkers to differentiate between different types of polyneuropathy and to investigate the underlying pathomechanisms is therefore of great importance. Therefore, nerve samples from patients suffering from chronic inflammatory demyelinating polyneuropathy (CIDP), axonal polyneuropathy or hereditary motor and sensory neuropathy (HMSN) type I were compared to each other and to a control group using RNA sequencing. Genes of certain functional groups were identified as significantly dysregulated, indicating general changes in the context of nerve damage from various causes. In addition, potential candidate genes could be identified that play a role in the development of specific diseases and could be used to differentiate between different types of polyneuropathy, as well as individual genes that are co-regulated in different types of polyneuropathy and thus provide an approach for research into common pathomechanisms and therapeutic approaches. TRIM36, LAMA1 and LGI2, which were significantly dysregulated in all groups studied, are likely to be of particular interest for further research.
Keywords: biomarker; chronic inflammatory demyelinating polyneuropathy; hereditary motor and sensory neuropathy; RNA sequencing; gene expression; nerve biopsy; peripheral neuropathy